Phase 3
Completed N=60
A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial
Source: ClinicalTrials.gov NCT04263987 ↗Enrolled (actual)
60
Serious AEs
11.7%
Results posted
Mar 2022
Primary outcomePrimary: Operative Time — 101; 126 minutes
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Holmium laser enucleation of the prostate (HOLEP) has proven to be efficacious and safe for the treatment of benign prostatic hypertrophy (BPH). New laser technologies such as the Moses Pulse laser system provide for improved energy delivery which may decrease blood loss and operative time. We seek to evaluate Moses technology for enucleation of the prostate in the setting of BPH.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Operative Time |
101; 126 | — |
| SECONDARY Percentage of Change of Hematocrit |
6; 9 | — |
Eligibility Criteria
Inclusion Criteria
- Any man with clinical symptoms fo BPH requiring surgery who has a prostate sized at greater than 80 grams
Exclusion Criteria
- Anyone actively on anticoagulation perioperatively
Data sourced from ClinicalTrials.gov (NCT04263987). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.